Sanuwave Health (SNWV)
NASDAQ:SNWV
Want to see SNWV full AI Analyst Report?
SNWV Stock Chart & Stats
$31.30
$1.30(5.42%)
At close: 4:00 PM EST
$31.30
$1.30(5.42%)
Day’s Range― - ―
52-Week Range$15.36 - $46.59
Previous CloseN/A
Volume17.14K
Average Volume (3M)78.76K
Market Cap
$141.63M
Enterprise Value$138.03M
Total Cash (Recent Filing)$10.78M
Total Debt (Recent Filing)$7.18M
Price to Earnings (P/E)8.5
Beta1.11
Next Earnings
Aug 18, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.75
Shares Outstanding8,598,976
10 Day Avg. Volume75,518
30 Day Avg. Volume78,757
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)157.84
Price to Sales (P/S)5.80
P/FCF Ratio132.13
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue3.11
Enterprise Value/Gross Profit4.11
Enterprise Value/Ebitda6.15
Forecast
1Y Price Target
$51.00Price Target Upside62.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.08
Revenue Forecast (FY)$51.35M
Bulls Say, Bears Say
Bulls Say
Installed Base & ConsumablesA growing installed base and rising consumables use create recurring revenue and longer customer lifetime value. Durable demand per system (consumables + usage) strengthens revenue visibility and supports scaling economics as each new system yields ongoing consumable sales.
High Margins & Cash GenerationSustained high gross margin alongside positive operating and free cash flow provides a structural ability to fund operations and reinvest in commercial/R&D. Strong margins and cash conversion improve resilience and lower funding needs despite prior volatility.
Maintained Guidance & Enterprise PipelineManagement maintaining guidance while reporting larger-account engagement signals durable commercial momentum. Progress in enterprise evaluations can scale recurring revenue and reduce concentration risk if conversions continue, supporting multi‑quarter growth visibility.
Bears Say
Thin Equity & LeverageHigh leverage and a history of thin or negative equity materially raise refinancing and solvency risk. Even with improved earnings, limited balance-sheet cushion reduces flexibility to absorb setbacks and increases probability that future growth requires dilutive or costly financing.
Margin Pressure From Channel MixA structural shift toward reseller/wholesale channels that lowers ASPs can persistently compress revenue per unit and margins. Combined with rising opex and one‑time costs, this mix change challenges margin sustainability unless pricing, mix or cost controls offset lower unit economics.
Regulatory & Reimbursement DisruptionOngoing CMS actions and reimbursement uncertainty create structural headwinds: longer sales cycles, higher churn among smaller providers, and constrained adoption in rural markets. These regulatory risks can persistently reduce utilization and complicate revenue predictability.
Sanuwave Health News
SNWV FAQ
What was Sanuwave Health’s price range in the past 12 months?
Sanuwave Health lowest stock price was $15.36 and its highest was $46.59 in the past 12 months.
What is Sanuwave Health’s market cap?
Sanuwave Health’s market cap is $141.63M.
When is Sanuwave Health’s upcoming earnings report date?
Sanuwave Health’s upcoming earnings report date is Aug 18, 2026 which is in 77 days.
How were Sanuwave Health’s earnings last quarter?
Sanuwave Health released its earnings results on May 12, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.14 by -$0.03.
Is Sanuwave Health overvalued?
According to Wall Street analysts Sanuwave Health’s price is currently Undervalued.
Does Sanuwave Health pay dividends?
Sanuwave Health does not currently pay dividends.
What is Sanuwave Health’s EPS estimate?
Sanuwave Health’s EPS estimate is -0.03.
How many shares outstanding does Sanuwave Health have?
Sanuwave Health has 8,598,976 shares outstanding.
What happened to Sanuwave Health’s price movement after its last earnings report?
Sanuwave Health reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.14. Following the earnings report the stock price went up 18.08%.
Which hedge fund is a major shareholder of Sanuwave Health?
Currently, no hedge funds are holding shares in SNWV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sanuwave Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$51.00 (62.94% Upside)
$51.00 (62.94% Upside)
Blogger Sentiment
Bullish
SNWV Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
32.00%
12-Months-Change
Fundamentals
Return on Equity
-450.56%
Trailing 12-Months
Asset Growth
20.23%
Trailing 12-Months
Company Description
Sanuwave Health
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.
SNWV Company Deck
SNWV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed cautious optimism: underlying demand signs and product adoption are improving (record applicator units, active systems growth, strong consumables usage, a growing large‑account pipeline, maintained full‑year guidance), but near‑term profitability metrics show pressure (gross margin compression, higher operating expenses, negative GAAP EBITDA) driven by reseller mix, one‑time remediation costs and market disruption from CMS actions. Management presents the issues as largely transitory and supported by a strengthening commercial pipeline.View all SNWV earnings summariesSNWV Stock 12 Month Forecast
Average Price Target
$51.00
▲(62.94% Upside)
Technical Analysis
Cerus
―
Senseonics Holdings
―
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Ownership Overview
26.10% Insiders
7.38% Mutual Funds
25.22% Other Institutional Investors
33.45% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---